| Company Name: |
Suzhou Meishi Biotechnology Co., Ltd.
|
| Tel: |
1173954148q |
| Email: |
meishipharma@126.com |
| Products Intro: |
Product Name:534605-78-2
CAS:534605-78-2
Purity:99% HPLC Package:1G;5G;10G;100G;1KG;
|
|
| Product Name: | TP3076 | | Synonyms: | CH-0793076;TP3076;10H,13H-Pyrano[3'',4'':6',7']indolizino[2',1':5,6]pyrido[4,3,2-de]quinazoline-10,13-dione, 9-ethyl-1,9,12,15-tetrahydro-9-hydroxy-1-pentyl-, (9S)- | | CAS: | 534605-78-2 | | MF: | C26H26N4O4 | | MW: | 458.51 | | EINECS: | | | Product Categories: | | | Mol File: | 534605-78-2.mol |  |
| | TP3076 Chemical Properties |
| Boiling point | 845.3±75.0 °C(Predicted) | | density | 1.46±0.1 g/cm3(Predicted) | | pka | 11.22±0.20(Predicted) |
| | TP3076 Usage And Synthesis |
| Description | TP-300, also known as CH-0793076; TP-3076, is a DNA topoisomerase I inhibitor potentially for the treatment of colorectal cancer, gastric cancer. TP300 is stable in an acidic solution but is rapidly converted to CH0793076 under physiological pH conditions such as in sera. This efficient prodrug activation would minimize interpatient differences in pharmacokinetic and toxicity profiles. Unlike CPT-11, TP300 does not exhibit cholinergic interaction or cause acute diarrhea at effective doses. In mouse xenograft models, TP300 showed antitumor activity against both BCRP-positive and -negative xenografts, whereas CPT-11 was less active against BCRP-positive xenografts. |
| | TP3076 Preparation Products And Raw materials |
|